Lantheus Wins FDA Approval for BRAVNETSA as LUTATHERA Bioequivalent

Key Facts

1Lantheus received final FDA approval for BRAVNETSA for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

2The FDA determined the radiopharmaceutical is bioequivalent and therapeutically equivalent to Novartis' LUTATHERA.

In a move reflecting the intensifying competition within the radiopharmaceutical sector, Lantheus Holdings has secured final FDA approval for its drug BRAVNETSA. The approval specifically covers the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This regulatory milestone marks a significant commercial step for the company as it enters a specialized oncology market previously dominated by established incumbents.

According to reports, the FDA has determined that BRAVNETSA is both bioequivalent and therapeutically equivalent to Novartis' LUTATHERA. This designation allows Lantheus to position its product as a direct alternative to the market leader, potentially shifting the competitive landscape for radiopharmaceutical treatments. The company's ability to commercialize this bioequivalent will be a key factor for its growth in the biotech space.

Market data shows LNTH closed at $100.28 (close September 21, 2026), having traded within a daily range of $100.22 to $100.96. Investors should monitor broader market catalysts, including the Fed Interest Rate Decision scheduled for later today, September 22, which remains a primary driver for sentiment across the healthcare and growth-stock sectors.